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Background: Coactivator-associated arginine methyltransferase 1 (CARM1) belongs to the protein arginine
methyltransferase family. CARM1 has been reported to be associated with high grade tumors in breast cancer. It still
remains unknown the expression pattern of CARM1 in breast cancer and its relationships with clinicopathological
characteristics and molecular subtypes.
Methods: Two hundred forty-seven invasive breast cancer cases were collected and prepared for tissue array. There
were thirty-seven tumors with benign glandular epithelium adjacent to the tumors among these cases. Molecular
subtype and CARM1 expression were investigated using immunohistochemistry.
Results: Cell staining was observed in the cytoplasm and/or nucleus. Staining for CARM1 was significantly stronger
in adenocarcinoma compared with adjacent benign epithelium. There is a significant correlation between CARM1
overexpression with young age, high grade, estrogen receptor (ER) and progesterone receptor (PR) negative,
increased p53 expression, and high Ki-67 index. Our study demonstrated CARM1 overexpression was associated
with an increase in the protein expression of HER2. Furthermore, our data indicated CARM1-overexpression rate
were remarkably higher in HER2 subtype (69.6%), luminal B subtype (59.6%) and TN subtype (57.1%) compared with
luminal A subtype (41.3%).
Conclusions: CARM1 expression was increased in invasive breast cancer. CARM1 overexpression was associated
with poorly characterized clinicopathologic parameters and HER2 overexpression. There were significant differences
between different molecular subtypes in their relationship to CARM1 overexpression. Our results support the value
of using CARM1 in prognostic stratification of breast cancer patients and its potential therapeutic implications in
targeting treatment.
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vs/4116338491022965
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Breast cancer is the most common cancer of woman in
many countries [1]. Human breast carcinomas represent
a collection of diverse tumors that vary in their natural
history and responsiveness to therapy. Because of its het-
erogeneity, many tumor tissue biomarkers have been
identified and used in breast cancer diagnosis to classify
subsets, indicate specific therapies and predict tumor
behavior. Today, biomarkers such as estrogen receptor
(ER), progesterone receptor (PR), p53, Ki-67 and human
epidermal growth factor receptor type 2 (HER2) guide
treatment decisions and prognosis.
HER2 is a proto-oncogene and is a member of the
HER gene family, which includes HER1 (epidermal
growth factor receptor, EGFR/erbB1), HER2, HER3
(erbB3) and HER4 (erbB4). The receptor is amplified or
overexpressed (or both) in approximately 18–20% of
breast cancers [2]. HER2 promotes cell proliferation and
angiogenesis and inhibits apoptosis via several pathways
[2], and HER2-positive status is a negative prognostic
factor [3,4]. Treating HER2-positive breast cancer with
anti-HER2 monoclonal antibodies, such as trastuzumab,
has markedly improved the outcome of this disease [5].
One major challenge to targeted therapy, however, is ac-
quired and primary resistance. Acquired resistance even-
tually develops in most patients in the advanced disease
setting [6]. Advances in molecular biology have led to
the identification of potential markers of prognostic and
therapeutic importance in breast cancers.
Methylation of histones by protein arginine methyl-
transferases (PRMTs) is increasingly being acknowledged
as an important aspect for the dynamic regulation of gene
expression. CARM1 (coactivator-associated arginine me-
thyltransferase 1) is a kind of type I protein arginine
methyltransferase that catalyzes the formation of asym-
metric dimethylarginine [7]. It initially was described as a
transcriptional activator of the p160 family of nuclear
receptor-associated proteins [8]. The p160 family includes
steroid receptor coactivators-1(SRC-1), SRC-2 and SRC-3
/AIB1 (amplified in breast cancer 1) [8]. CARM1 functions
as a coactivator for many nuclear receptors (NRs) [9,10],
including ERα [11]. ERα plays a pivotal role in promoting
the proliferation of several types of estrogen-stimulated
breast cancer [12]. CARM1 has also been shown to be a
molecular switch that controls multiple classes of gene-
specific transcription factors, including p53, NF-κB, LEF1/
TCF4, E2Fs, and cyclin E1 [9,13-16]. These suggest this
enzyme plays pleiotropic roles in cell proliferation and sur-
vival. Some researchers had investigated the expression of
CARM1 in many kinds of malignant tumors [17-19]. Ab-
errant expression of CARM1 has been linked to human
breast cancer tissue in a few reports [13,16,17]; however,
current studies are contradictory and incomplete. The
mRNA level of CARM1 was found to be elevated in grade3 breast tumors in a cohort of 81 human breast carcin-
omas of various types [16]. While another study demon-
strated there was inverse correlation between CARM1
expression and tumor grade in ER + and LN-breast cancer
cases [13]. Kim YR et al. reported CARM1 overexpression
was noted only in small number of breast cancer patients
(27%) [17]. All these reports suggest CARM1 is an import-
ant factor involved in progression and may affect prognos-
tication of breast cancer. However, many of these studies
were limited either by low n values of breast cancer pa-
tients or by a special tumor type. It still remains unclear
whether CARM1 expression is correlated with clinicopath-
ological features, molecular subtype and prognosis.
The aim of this study was to characterize the CARM1
expression pattern in invasive breast carcinoma and to
analyze its relationship with clinicopathologic character-
istics, including the expression of ER, PR, HER2, p53
and Ki-67 index. Additionally, we compared the expres-
sion of CARM1 in different molecular subtypes to assess
its potential value in improving patient stratification and
guiding personal patient management.
Methods
Tumor samples and clinical material
Two hundred forty-seven untreated breast tumor samples
were collected from the pathology department at Provincial
Hospital and Qilu Hospital affiliated to Shandong Univer-
sity from March 2007 to March 2009. There were thirty-
seven tumors with benign glandular epithelium adjacent to
the tumors. Tumor tissue was collected and processed for
immunohistochemistry using a tissue microarray. All the
diagnoses were made by two pathologists following the
WHO Classification of Tumors of the Breast (2012) [20].
Lymph node metastases were present in 119 patients (48.6%)
at the time of surgery; these metastases were detected in
the final paraffin sections. Tumor stage was based on
American Joint Committee on Cancer (AJCC) TNM sta-
ging system [21], and histological grade used the Elston
and Ellis modification of the Scarff-Bloom-Richardson
grading system [22]. Estimations of tumor grade were
scored simultaneously by two investigators blinded to the
patient’s clinical findings. In case of different views, a third
independent investigator provided an opinion. Patients
with the following characteristics were excluded from this
study: patients who accepted therapy before surgery; tumor
histology other than invasive ductal or lobular carcinoma;
cases with incomplete data on ER, PR, or HER2. For the
use of these clinical materials for research purposes, prior
patient content and approval from the Institutional Re-
search Ethics Committee of our hospitals were obtained.
Immunohistochemistry
All 247 breast samples were fixed in formalin and em-
bedded in paraffin wax. Immunohistochemical staining
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plex method on 4 μm thick sections. After being
deparaffinized with xylenes and rehydrated, sections
were submerged into 10 mM citrate buffer (pH 6.0) and
microwaved for 15 min to retrieve the antigens, followed
by incubation in 3% H2O2 for 10 minutes to quench en-
dogenous peroxidase. Nonspecific binding of antibodies
was inhibited by incubation in 5% normal goat serum.
Rabbit anti-CARM1 antibody (dilution 1:50, Upstate
Biotechnology, Lake Placid, NY) was incubated with the
sections overnight at 4°C; the second antibody was from SP
reagent kit (Zhongshan Biotechnology Company, Beijing,
China). After washing, tissue sections were incubated with
biotinylated anti-rabbit secondary antibody, and then in-
cubated in streptavidin-peroxidase complex. In addition,
the sections were stained with diaminobenzidine (DAB)
and counterstained with hematoxylin. For negative con-
trols, sections were incubated in PBS instead of the primary
antibody. We also used a control IgG to prove that there
were no non-specific reactions of the CARM1 antibody.
Assessment of immunohistochemical staining
The immunostained slides were evaluated by two patholo-
gists independently in a blind fashion. Immunohistochem-
istry scores of CARM1 derived from the assessment of
both staining intensity and percentage of positive cancer
cells as described previously [23]. Nuclear and plasmid
staining was scored separately. Intensity of staining was
grade as 0–3(0, no staining; 1, weak staining; 2, unequivo-
cal moderate staining; and 3, strong staining). The per-
centage of positive staining cells was recorded in
increments of 10%, from 0 to 100%. These two scores
were multiplied to generate an immunohistochemical
score (IHC score) generate with a range of 0–300.
Positive staining for ER, PR and p53 was defined as
staining of >10% of nuclei,and an elevated Ki-67 index
was also defined as >10% tumor cells with distinctly
positive nuclear staining. HER2-positivity was defined
as 3(+) on IHC staining or HER2 gene amplification by
fluorescence in situ hybridization (FISH). FISH was
performed selectively when the score was 2(+).
Classification of molecular subtypes
In breast cancer, utilization of immunohistochemistry as a
surrogate for molecular classification by gene expression
profiling has been used in a number of large population-
based studies and has been shown to provide an acceptable
level of accuracy for determining molecular phenotype
[24,25]. Different subtypes of tumors were shown to have
different tumor biology, different prognoses, and different
responses to therapy. Molecular subtypes were approxi-
mated using histological grade and the ER, PR, and HER2
status of the primary tumor [26]. Cases that were ER-positive
and/or PR-positive, HER2-negative and either histologicgrade 1 or 2 were classified as luminal A cancers; cases that
were ER-positive and/or PR-positive and HER2-positive, or
ER-positive and/or PR-positive, HER2-negative and histo-
logic grade 3 were classified as luminal B cancers; cases that
were ER-negative, PR-negative, and HER2-positive were
classified as HER2 type; and cases that were negative for
ER, PR, and HER2 were classified as triple negative(TN).
Analysis
Statistical analysis was carried out using SPSS 11.0. The
statistical analysis of CARM1 expression between be-
nign and tumor tissue was performed with the one-way
ANOVA. The correlation between CARM1 expression
and clinicopathological parameters, CARM1 expression
and universal biological factors, and CARM1 expression in
different subtypes were examined using chi-square test
or Fisher’s exact test if appropriate. Bivariate correlations
between study variables were calculated by Spearman’s rank
correlation coefficient. Positive nuclear and cytoplasmic
staining for CARM1 was estimated separately. Differences
were considered statistically significant for p values < 0.05.
Results
Expression of CARM1 in breast invasive carcinoma
To determine the pattern of CARM1 expression in inva-
sive breast cancer, tissue microarrays containing cancer
tissue with several adjacent benign tissues were used for
immunohistochemical staining of CARM1. In the 37 tu-
mors with matching benign tissues adjacent to the tu-
mors, most benign breast epithelial cells exhibited
negative or weak staining for CARM1 (mean IHC score,
nuclear 50.00, cytoplasm 37.57); staining for CARM1
was significantly stronger in matched adenocarcinoma
cells (mean IHC score, nuclear 111.35, cytoplasm
87.57). The increased expression was observed in the
cytoplasm and/or the nucleus (Figure 1). The differ-
ences between malignant tissue specimens and benign
epithelium were statistically significant (one-way ANOVA,
nuclear p < 0.001, cytoplasmic p < 0.001, Figure 1).
CARM1 expression in breast invasive carcinoma showed
nuclear and/or cytoplasmic staining patterns, and each
was scored separately. In positive samples, a large number
of cases were stained in the nucleus and cytoplasm, while
some cases showed either mainly nuclear or cytoplasmic
staining pattern (Figure 1). Our results indicated 126 of
247 (51.0%) patients showed nuclear positive and 142 of
247 (57.5%) showed cytoplasmic positive (Tables 1 and 2).
Relationship of CARM1 overexpression with the
clinicopathologic characteristics of breast invasive carcinoma
When we correlated CARM1 expression with clinico-
pathologic parameters, we found expression of CARM1
in the nucleus was strongly correlated with the patients’
age at diagnosis (p = 0.002), tumor number (p <0.001) and
Figure 1 The expression pattern of CARM1 in human invasive breast cancer (×400). A In positive samples, the expression of CARM1 in
adenocarcinomas was considerably increased compared with the adjacent benign glandular epithelium (A and B). The increased expression was
both nuclear and cytoplasmic (C), predominantly nuclear (D), or predominantly cytoplasmic (E). A representative negative case is shown
(F). Asterisks indicate adenocarcinoma. Arrows indicate benign breast epithelium. B CARM1 expression was increased significantly in invasive
breast cancer compared with benign epithelium (one-way ANOVA P < 0.001).
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other clinical characteristics (Table 1). Spearman correlation
analysis was further preformed to confirm the correlation
between nuclear CARM1 overexpression and patients’
age, tumor number and grade status, which were −0.197
(p = 0.002), 0.231(p < 0.001) and 0.134(p = 0.035) respect-
ively. Cytoplasmic CARM1 expression was only correlated
with the patients’ age at diagnosis (p = 0.041) and tumor
grade (p = 0.019, Table 2). Spearman correlation of cyto-
plasmic CARM1 expression levels to them were −0.130
(p = 0.041) and 0.149 (p = 0.019), respectively. These results
indicated CARM1 overexpression was correlated with poor
clinicopathologic characteristics.
Correlation of hormone receptor, HER2, Ki-67 and p53
with CARM1 overexpression
Staining for CARM1 in the cytoplasm and the nucleus
were analyzed separately. We found that in the entire
cohort of tumors, CARM1 expression in the nucleus
was correlated with ER (p = 0.016), PR (p = 0.007),
HER-2 (p = 0.037), Ki-67 (p = 0.014) and p53 (p = 0.006),which was further confirmed by Spearman correlation
analysis. Nuclear expression of CARM1 was negatively
correlation with ER (r = −0.153, p = 0.016) and PR levels
(r = −0.173, p = 0.006), and positively correlation with
HER-2 (r = 0.132, p = 0.038), Ki-67 (r = 0.157, p = 0.014)
and p53 (r = 0.174, p = 0.006). While there was signifi-
cant difference between cytoplasmic CARM1 expres-
sion and expression levels of ER (r = −0.175, p = 0.006), PR
(r = −0.129, p = 0.043), and Ki-67 (r = −0.150, p = 0.018).
The results suggested overexpression of CARM1 was
correlated with aggressive action and poor prognosis.
Relationship of CARM1 expression with different subtypes
of invasive breast carcinoma
To determine the role of CARM1 expression in different
subtypes of invasive breast carcinoma, we correlated the
nuclear expression of CARM1 with tumor molecular
subtypes (Table 3). We found that the nuclear expres-
sion of CARM1 was significantly different among four
molecular subtypes (p = 0.019), while CARM1 expres-
sion in the cytoplasm was not (p = 0.066). We showed




n Nuclear CARM1 expression P﹡
Negative or low expression (IHC score < 80) High or over expression (IHC score f ≥ 80)
Age(y)
≤40 53 16 (30.2) 37 (69.8) 0.002
>40 194 105 (54.1) 89 (45.9)
Tumor size
≤2 cm 125 65 (52.0) 60 (48.0) 0.338
>2 cm 122 56 (45.9) 66 (54.1)
Tumor number
1 234 121 (51.7) 113 (48.3) <0.001
≥2 13 0 (0) 13 (100.0)
Grade
I&II 181 96 (53.0) 85 (47.0) 0.035
III 66 25 (37.9) 41 (62.1)
Lymph node metastasis
N0 127 56 (44.1) 71 (55.9) 0.113
N1, N2,N3 120 65 (54.2) 55 (45.8)
TNM stage
I 74 36 (48.6) 38 (51.4) 0.886
II 111 53 (47.7) 58 (52.3)
III 62 32 (51.6) 30 (48.4)
ER
negative 90 35 (38.9) 55 (61.1) 0.016
positive 157 86 (54.8) 71 (45.2)
PR
negative 136 56 (41.2) 80 (58.8) 0.007
positive 111 65 (58.6) 46 (41.4)
HER2
negative 206 107 (51.9) 99 (48.1) 0.037
positive 41 14 (34.1) 27 (65.9)
Expression of Ki67
low (≤10%) 55 35 (63.6) 20 (36.4) 0.014
high (>10%) 192 86 (44.8) 106 (55.2)
Expression of P53
low 95 57 (60.0) 38 (40.0) 0.006
high 152 64 (42.1) 88 (57.9)
﹡ P value is the result of χ2 test in the same factor, and < 0.05 is considered statistically significant.
Cheng et al. Diagnostic Pathology 2013, 8:129 Page 5 of 9
http://www.diagnosticpathology.org/content/8/1/129that in the HER-2 subtype, the nuclear expression of
CARM1 was the highest (69.6%), followed by the lu-
minal B (59.6%) and basal type (57.1%). The luminal
A type showed the lowest percentage of cells with
CARM1 nuclear expression (41.3%). Compared with
luminal A, luminal B, HER-2, and basal type are cor-
related with a generally more aggressive tumor pheno-
type and poorer prognosis [25]. These results suggestthat CARM1 overexpression may also be correlated with
poor prognosis.
Discussion
Breast cancer is a heterogeneous disease encompassing
multiple subgroups with differing molecular signatures,
prognoses, and responses to therapies [27]. Other reasons
for heterogeneity may include differences in the studied




n Cytoplasmic CARM1 expression P﹡
Negative or low expression (IHC score < 80) High or over expression (IHC score ≥ 80)
Age(y)
≤40 53 16 (30.2) 37 (69.8) 0.041
>40 194 89 (45.9) 105 (54.1)
Tumor size
≤2 cm 125 57 (45.6) 68 (54.4) 0.320
>2 cm 122 48 (39.3) 74 (60.7)
Tumor number
1 234 101 (43.2) 133 (56.8) 0.379
≥2 13 4 (30.8) 9 (69.2)
Grade
I&II 181 85 (47.0) 96 (53.0) 0.019
III 66 20 (30.3) 46 (69.7)
Lymph node metastasis
N0 127 48 (37.8) 79 (62.2) 0.123
N1, N2,N3 120 57 (47.5) 63 (52.5)
TNM stage
I 74 30 (40.5) 44 (59.5) 0.384
II 111 44 (39.6) 67 (60.4)
III 62 31 (50.0) 31 (50.0)
ER
negative 90 28 (31.1) 62 (68.9) 0.006
positive 157 77 (49.0) 80 (51.0)
PR
negative 136 50 (36.8) 86 (63.2) 0.043
positive 111 55 (49.5) 56 (50.5)
HER2
negative 206 93 (45.1) 113 (54.9) 0.060
positive 41 12 (29.3) 29 (70.7)
Expression of K-i67
low (≤10%) 55 31 (56.4) 24 (43.6) 0.018
high (>10%) 192 74 (38.5) 118 (61.5)
Expression of P53
low 95 45 (47.4) 50 (53.6) 0.222
high 152 60 (39.5) 92 (60.5)
﹡ P value is the result of χ2 test in the same factor, and < 0.05 is considered statistically significant.
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be due to interaction with other risk factors (e.g., BRCA
variants) [28]. El FH found that molecular classification
and biological profile may be different according to
geographical distribution [29]. Zhang Q’s study showed
the ectopic expression of BRCA1 was associated with the
genesis, progression, and prognosis in young breast cancer
patients [30]. Finding of the sources of heterogeneitywould contribute to patient’s stratification and personal-
ized treatment. Our study demonstrated that nuclear
CARM1 expression was associated with a younger age at
diagnosis; a higher tumor grade; a higher rate of HER2,
p53, and ki-67 expression; and a lower rate of ER and PR
expression in breast cancer patients of Chinese women.
We also found that nuclear CARM1 expression was
significant different among four molecular subtypes.
Table 3 Correlation between nuclear, cytoplasmic CARM1 expression and molecular subtypes of breast cancer patients
Molecular
subtypes
n Nuclear CARM1 expression P﹡ Cytoplasmic CARM1 expression P﹡
Negative or low expression
(IHC score < 80)
High or over expression
(IHC score ≥ 80)
Negative or low expression
(IHC score < 80)
High or over expression
(IHC score ≥ 80)
Lumina A 121 71 (58.7) 50 (41.3) 0.019 60 (49.6) 61 (50.4) 0.066
Luminal B 47 19 (40.4) 28 (59.6) 19 (40.4) 28 (59.6)
HER2 type 23 7 (30.4) 16 (69.6) 5 (21.7) 18 (78.3)
triple
negative
56 24 (42.9) 32 (57.1) 21 (37.5) 35 (62.5)
﹡ P value is the result of χ2 test in the same factor, and < 0.05 is considered statistically significant.
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sion, both in the cytoplasm and the nucleus, were more
remarkable in younger patients than in patients older
than 40 years of age. Young age at the time of diagnosis
of breast cancer is an independent factor of poor progno-
sis for reasons that are not fully understood [31,32]. Some
studies have demonstrated breast cancer at a younger age
might be associated with higher grade, ER-negativity, a
more advanced stage of the disease, ectopic expression of
BRCA1 [30], and higher levels of HER2. Previously, it has
been shown that embryonic stem cells overexpressing
CARM1 were more resistant to differentiation [33]. In our
study, the CARM1 overexpression in younger patients
was more common compared with older patients, and
might contribute to the clinical characteristics of younger
patients, such as lower differentiation. However, we be-
lieve it may not be the only factor.
Regarding the subcellular distribution of CARM1, it is
predominantly localized in the nucleus as a transcriptional
coactivator [34]. That is to say, most of the known func-
tions of CARM1 are related to its nuclear localization. A
few studies also revealed that CARM1 accumulates in the
cytoplasm during mitosis [14,34]. CARM1 S217E mutant
protein and a small percentage of wild-type CARM1 are
also localized in the cytosol [34]. This suggested CARM1
may play an unknown function in the cytoplasm [34]. Be-
cause nucleus is the principal subcellular localization of
CARM1 activation, we will focus on nuclear CARM1 ex-
pression hereinafter.
Our results indicated that CARM1 expression posi-
tively correlated with HER2 expression and grade, and
negatively correlated with hormone receptors in separate
analyses with universal molecular makers. The molecular
subtypes were also classified according to a panel of ER,
PR, and HER2 biomarkers combined with grade in our
study [31]. We will discuss the correlation between these
factors and CARM1 expression in different molecular
subtypes.
The luminal A subtype, known as the hormone subtype,
showed the lowest rate of CARM1 expression compared
with that in the other subtypes. Previous reports have
shown that CARM1 plays an essential role in estrogen-
mediated transcriptional activation [35,36], and is necessaryfor the estradiol (E2)-induced proliferation of breast cancer
cells [15]. The co-regulator requirement of CARM1 can
be highly tissue- and context-dependent [8,13,37]. Fur-
thermore, CARM1 transcriptional coactivating functions
are not restricted to nuclear receptors [16,33]. Consistent
with this concept, our result also shows only a small part
of luminal A subtype cancer tissue overexpress nuclear
CARM1.
Our study demonstrated that CARM1 overexpression
in breast cancer was associated with the overexpression of
HER2. Both HER-2 subtype (69.6%) and luminal B subtype
(59.6%) showed higher rate of CARM1 expression com-
pared with that in luminal A tumors. Within luminal B
subtype, HER2 signaling is dominant, as demonstrated by
the poor response of such tumors to endocrine therapy
alone. HER2 overexpression confers intrinsic or primary
resistance to hormone-based therapy despite the presence
of hormone receptors [38,39]. In this study, we showed
that there was a strong positive correlation between
CARM1 and HER2 expression. This suggests that CARM1
may be useful as a predictor of clinical outcomes in pa-
tients with HER2-positive tumors.
The mechanism of CARM1 and HER2 interaction, or
through which pathway they crosstalk, has not yet been
elucidated. One potential mechanism may be the tran-
scriptional coactivation mediated by CARM1 and p160.
CARM1 was initially described as a transcriptional
coactivator of the p160 nuclear receptor family [8]. All
members of the p160 family are natural substrates of
CARM1, which can bind and recruit CARM1 to syner-
gistically exert transcriptional co-activating functions of
target genes [40]. Multiple studies have demonstrated
that AIB1 (a member of the p160 family) mRNA and
protein expression in breast cancer is associated with
the expression of HER2. AIB1 was shown to play a role
in the regulation of the HER2 pathway [41]. Although
AIB1 expression was not examined in our study, data
from El Messaoudi S et al. showed that AIB1 and
CARM1 mRNA levels were both elevated in breast can-
cer, notably in grade 3 [16]. Our finding that CARM1
overexpression in breast cancer correlated with high
HER2 expression supports the hypothesis that CARM1
might play an important role in the regulation of the
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with the p160 family.
TN breast cancer is associated with poor prognosis
because it lacks the benefit of specific therapy. The TN
subtype group encompasses a number of distinct entities
with defined gene expression profiles and outcomes [39].
Our results revealed that over half of the TN tumors
overexpressed nuclear CARM1. These results suggest
that monitoring the level of CARM1 expression might be
valuable to distinguish different entities of TN tumors.
Future research should explore this hypothesis as well as
its clinical applicability
In summary, based on previous work and the results
presented here, CARM1 may promote tumor cell growth
by activating nuclear receptors and multiple growth fac-
tor signaling cascades in breast cancer. However, the
predominance of which pathway is regulated by CARM1
depends on the tumor phenotype. CARM1 requires its
enzymatic activity for all of its known nuclear functions.
Thus, specific and potent small molecule inhibitors of
CARM1 will incapacitate all of its nuclear functions
[42]. Additionally, chemotherapeutic drugs targeted at
CARM1 will likely interfere with several pathways con-
comitantly. Therefore, targeted therapy of CARM1 is
promising and warrants further exploration.
One limitation of the study is that we didn’t know the
relationship of CARM1 overexpression and the prognosis
of breast cancer. It still remains unclear about the accurate
regulative pathways mentioned above in cancer cells. All
these need to be explored by further study.
Conclusions
In this study, we demonstrated that CARM1 expression
was increased in invasive breast cancer cells compared
with adjacent benign epithelium. Nuclear CARM1 ex-
pression was associated with a younger age at diagnosis;
multi-center origin or multiple tumors; a higher tumor
grade; a higher rate of HER2, p53, and Ki-67 expression;
and a lower rate of ER and PR expression. All of these
predictors are clinicpathologic parameters that correlate
with poor prognosis. This suggests that CARM1 might
have the potential to improve the stratification and per-
sonal management of patients suffering from breast can-
cer. We also found that the rate of CARM1 expression
was significantly different among different molecular
subtypes of breast cancer, which may hint at a different
mechanism and prognosis value. This should be further
investigated.
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